| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/2159-8290.CD-17-1119 |
| P698 | PubMed publication ID | 29247021 |
| P50 | author | Keith Flaherty | Q6384357 |
| Antoni Ribas | Q32649604 | ||
| Mario Sznol | Q66809426 | ||
| Filip Janku | Q73569186 | ||
| Elizabeth I Buchbinder | Q88566597 | ||
| Jeffrey A Sosman | Q114291532 | ||
| Jeffrey R Infante | Q114439514 | ||
| P2093 | author name string | Ryan J Sullivan | |
| Geoffrey I Shapiro | |||
| Anthony W Tolcher | |||
| Mario E Lacouture | |||
| Vicki Keedy | |||
| David M Hyman | |||
| James W Mier | |||
| Saurabh Saha | |||
| Andrea Wang-Gillam | |||
| Richard D Carvajal | |||
| Manish R Patel | |||
| Sapna P Patel | |||
| Anna L Groover | |||
| Caroline M Emery | |||
| Bob T Li | |||
| Anna M Varghese | |||
| Dean J Welsch | |||
| Gary A DeCrescenzo | |||
| Mary Varterasian | |||
| Deborah Jean Lee Wong | |||
| P2860 | cites work | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| P577 | publication date | 2017-12-15 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study |
| Q93367319 | A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers |
| Q92716634 | A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors |
| Q91272659 | A view on drug resistance in cancer |
| Q49790712 | Accelerating Discovery of Functional Mutant Alleles in Cancer |
| Q92988012 | BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors |
| Q91719232 | BRAF in the cross-hairs |
| Q47104481 | BRAF inhibitors: resistance and the promise of combination treatments for melanoma |
| Q91564745 | Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium |
| Q64069077 | Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer |
| Q90671653 | Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models |
| Q89860520 | Current Advances in the Treatment of BRAF-Mutant Melanoma |
| Q58570579 | Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma |
| Q52691585 | Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. |
| Q92581702 | Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer |
| Q101059327 | Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers |
| Q64275525 | ERK Activity Imaging During Migration of Living Cells In Vitro and In Vivo |
| Q52617939 | Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies. |
| Q92000430 | Endothelial life discontinues without Erk |
| Q92914123 | Evaluation of ERK as a therapeutic target in acute myelogenous leukemia |
| Q57795889 | Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells |
| Q89829094 | Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival |
| Q93079092 | Highlights in Resistance Mechanism Pathways for Combination Therapy |
| Q60939319 | How the V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications |
| Q100762000 | Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling |
| Q92618729 | Increased CDK4 protein expression predicts a poor prognosis in mucosal melanoma associated with the p16INK4a-CDK4-pRb pathway |
| Q91708382 | Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects |
| Q90403050 | MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology |
| Q92631849 | Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer |
| Q91344488 | Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo |
| Q90250949 | Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis |
| Q64077384 | Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia |
| Q58079189 | Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies |
| Q52690032 | Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics. |
| Q91162949 | Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway |
| Q91522252 | Pyrazine ring-based Na+/H+ exchanger (NHE) inhibitors potently inhibit cancer cell growth in 3D culture, independent of NHE1 |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q90357648 | Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy |
| Q54975597 | Synthesis, Molecular Structure, Anticancer Activity, and QSAR Study of N-(aryl/heteroaryl)-4-(1H-pyrrol-1-yl)Benzenesulfonamide Derivatives. |
| Q92780387 | Systematic Functional Interrogation of Genes in GWAS Loci Identified ATF1 as a Key Driver in Colorectal Cancer Modulated by a Promoter-Enhancer Interaction |
| Q91632717 | Targeting Alterations in the RAF-MEK Pathway |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
| Q92702616 | Targeting Oncogenic BRAF: Past, Present, and Future |
| Q93166415 | Targeting autophagy-related protein kinases for potential therapeutic purpose |
| Q89519692 | The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer |
| Q57060145 | Therapeutic strategies to target RAS-mutant cancers |
Search more.